Nasopharyngeal carcinoma screening
|
Nasopharyngeal carcinoma Microchapters |
|
Differentiating Nasopharyngeal carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Nasopharyngeal carcinoma screening On the Web |
|
American Roentgen Ray Society Images of Nasopharyngeal carcinoma screening |
|
Risk calculators and risk factors for Nasopharyngeal carcinoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]Faizan Sheraz, M.D. [3]
Overview
Screening for nasopharyngeal carcinoma only is done in endemic areas. Different methods, such as measurement the titre of different types of antibodies against EBV and plasma EBV DNA, and endoscopic examination of nasopharynx can be used for screening.
Screening
Screening for nasopharyngeal carcinoma only is done in endemic areas, the screening methods which can be used are:[1][2][3][4][5][6][7][8]
- Measuring the titre levels of:
- Endoscopic examination of nasopharynx
References
- ↑ Altun, M.; Fandi, A.; Dupuis, O.; Cvitkovic, E.; Krajina, Z.; Eschwege, F. (1995). "Undifferentiated nasopharyngeal cancer (UCNT): Current diagnostic and therapeutic aspects". International Journal of Radiation Oncology*Biology*Physics. 32 (3): 859–877. doi:10.1016/0360-3016(95)00516-2. ISSN 0360-3016.
- ↑ Wang, W.-Y.; Twu, C.-W.; Chen, H.-H.; Jan, J.-S.; Jiang, R.-S.; Chao, J. Y.C.; Liang, K.-L.; Chen, K.-W.; Wu, C.-T.; Lin, J.-C. (2010). "Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma". Clinical Cancer Research. 16 (3): 1016–1024. doi:10.1158/1078-0432.CCR-09-2796. ISSN 1078-0432.
- ↑ Y. Zeng, L. G. Zhang, Y. C. Wu, Y. S. Huang, N. Q. Huang, J. Y. Li, Y. B. Wang, M. K. Jiang, Z. Fang & N. N. Meng (1985). "Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China". International journal of cancer. 36 (5): 545–547. PMID 4055129. Unknown parameter
|month=ignored (help) - ↑ Y. S. Zong, J. S. Sham, M. H. Ng, X. T. Ou, Y. Q. Guo, S. A. Zheng, J. S. Liang & H. Qiu (1992). "Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma". Cancer. 69 (1): 3–7. PMID 1309307. Unknown parameter
|month=ignored (help) - ↑ Wei-min Cheng, Kwok Hung Chan, Hong-lin Chen, Rui-xian Luo, S. Park Ng, Winsie Luk, Bo-jian Zheng, Ming-fang Ji, Jin-sheng Liang, Jonathan S. T. Sham, De-Kun Wang, Yong-sheng Zong & Mun Hon Ng (2002). "Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum". International journal of cancer. 97 (4): 489–492. PMID 11802211. Unknown parameter
|month=ignored (help) - ↑ Chien, Yin-Chu; Chen, Jen-Yang; Liu, Mei-Ying; Yang, Hwai-I; Hsu, Mow-Ming; Chen, Chien-Jen; Yang, Czau-Siung (2001). "Serologic Markers of Epstein–Barr Virus Infection and Nasopharyngeal Carcinoma in Taiwanese Men". New England Journal of Medicine. 345 (26): 1877–1882. doi:10.1056/NEJMoa011610. ISSN 0028-4793.
- ↑ Yu, K. J.; Hsu, W.-L.; Pfeiffer, R. M.; Chiang, C.-J.; Wang, C.-P.; Lou, P.-J.; Cheng, Y.-J.; Gravitt, P.; Diehl, S. R.; Goldstein, A. M.; Chen, C.-J.; Hildesheim, A. (2011). "Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC Families". Clinical Cancer Research. 17 (7): 1906–1914. doi:10.1158/1078-0432.CCR-10-1681. ISSN 1078-0432.
- ↑ Leung, S.-f. (2004). "Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein-Barr Virus DNA and Anti-Epstein-Barr Viral Capsid Antigen IgA Antibody". Clinical Chemistry. 50 (2): 339–345. doi:10.1373/clinchem.2003.022426. ISSN 0009-9147.